Lamivudine Teva Pharma B.V (Lamivudine)

Lamivudine is a nucleoside analogue that, after intracellular phosphorylation, mimics the natural building block deoxycytidine triphosphate. It is incorporated by HIV reverse transcriptase and hepatitis B virus DNA polymerase into the growing viral DNA chain, where it causes premature termination, thereby blocking further viral genome synthesis and replication.

The dosage of lamivudine is individualized and must be determined by a qualified prescriber based on the patient’s clinical condition, weight, renal function, and any concomitant therapies. Health‑care professionals follow approved prescribing information and local guidelines to select the appropriate strength and dosing schedule.

Lamivudine may be used during pregnancy when the potential benefits outweigh potential risks to the fetus, and it is often included in combination regimens for preventing mother‑to‑child transmission of HIV. Limited data are available for breastfeeding; clinicians should assess the risk‑benefit ratio and consider alternative options if safety concerns arise.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Lamivudine Teva Pharma B.V. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class, offering a favorable safety profile and convenient oral dosing. Compared with some older NRTIs, it has lower mitochondrial toxicity and fewer hematologic side effects. It is frequently combined with other antiretrovirals to form potent regimens, whereas protease inhibitors or integrase inhibitors target different steps of the viral life cycle.

Lamivudine tablets should be stored at ambient temperature, preferably below 25 °C, in their original packaging to protect them from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to extreme heat or humidity, which could affect potency.

Lamivudine is administered orally, usually as a tablet taken with or without food. The exact timing and frequency depend on the prescriber’s instructions and the specific treatment regimen. Patients should follow the dosing schedule precisely and not skip doses without consulting their health‑care provider.

Serious adverse events, although rare, include lactic acidosis, severe hepatotoxicity, pancreatitis, Stevens‑Johnson syndrome, and severe hypersensitivity reactions. Patients should seek immediate medical attention if they experience unexplained abdominal pain, persistent nausea, vomiting, jaundice, rash, or signs of an allergic reaction.

Lamivudine is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Patients with severe renal impairment may require dose adjustment, and those with active hepatitis B flare or severe liver disease should be evaluated carefully before initiation.